Literature DB >> 27900499

Cardiac parasympathetic dysfunction in the early phase of Parkinson's disease.

Masashi Suzuki1, Tomohiko Nakamura2, Masaaki Hirayama3, Miki Ueda1, Masahisa Katsuno1, Gen Sobue4,5.   

Abstract

Cardiac parasympathetic function is strongly affected by aging. Although sympathetic dysfunction has been well documented in Parkinson's disease (PD), cardiac parasympathetic dysfunction has not been well studied. The objective of this study was to clarify the development of cardiac parasympathetic dysfunction in the early phase of PD and to explore the age-corrected correlation between cardiac parasympathetic dysfunction and cardiac sympathetic dysfunction. We reviewed 25 healthy controls and 56 patients with idiopathic PD of Hoehn and Yahr stages I-III. We evaluated cardiac parasympathetic function using the Valsalva ratio, the baroreflex sensitivity (BRS) and the coefficient of variation of RR intervals in the resting state (resting-CVRR) and during deep breathing (DB-CVRR). In addition, we measured cardiac 123I-metaiodobenzylguanidine (MIBG) uptake to investigate the relationship between cardiac sympathetic and parasympathetic dysfunction in PD. Compared with healthy controls, patients with PD showed significantly decreased cardiac parasympathetic parameters (resting-CVRR 2.8 ± 1.3 vs. 1.7 ± 0.6%, p < 0.001; DB-CVRR 5.8 ± 2.3 vs. 3.8 ± 1.7%, p < 0.001; Valsalva ratio 1.52 ± 0.26 vs. 1.34 ± 0.17, p < 0.01; BRS 10.6 ± 9.5 vs. 5.0 ± 5.4 ms/mmHg, p < 0.01). In particular, resting-CVRR and DB-CVRR were significantly decreased in the early phase of PD. In age-corrected analyses, none of the parasympathetic indices correlated with the delayed cardiac 123I-MIBG uptake. These observations indicate that cardiac parasympathetic dysfunction occurs in the early phase of PD, but not necessarily in parallel with cardiac sympathetic dysfunction.

Entities:  

Keywords:  Autonomic dysfunction; Autonomic nervous system; Cardiac 123I-metaiodobenzylguanidine scintigraphy; Cardiac parasympathetic dysfunction; Parkinson’s disease

Mesh:

Substances:

Year:  2016        PMID: 27900499     DOI: 10.1007/s00415-016-8348-0

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  32 in total

1.  Heart rate variability in patients with untreated Parkinson's disease.

Authors:  M Kallio; T Haapaniemi; J Turkka; K Suominen; U Tolonen; K Sotaniemi; V P Heikkilä; V Myllylä
Journal:  Eur J Neurol       Date:  2000-11       Impact factor: 6.089

2.  Reduced sympathetic activity in idiopathic rapid-eye-movement sleep behavior disorder and Parkinson's disease.

Authors:  Gertrud Laura Sorensen; Jesper Mehlsen; Poul Jennum
Journal:  Auton Neurosci       Date:  2013-08-27       Impact factor: 3.145

3.  Autonomic control of cardiac chronotropic function in man as a function of age: assessment by power spectral analysis of heart rate variability.

Authors:  O V Korkushko; V B Shatilo; T V Shatilo
Journal:  J Auton Nerv Syst       Date:  1991-03

4.  Valsalva manoeuvre in patients with different Parkinsonian disorders.

Authors:  C Schmidt; B Herting; S Prieur; S Junghanns; K Schweitzer; C Globas; L Schöls; H Reichmann; D Berg; Tjalf Ziemssen
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

5.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.

Authors: 
Journal:  Eur Heart J       Date:  1996-03       Impact factor: 29.983

6.  Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome.

Authors:  Roy Freeman; Wouter Wieling; Felicia B Axelrod; David G Benditt; Eduardo Benarroch; Italo Biaggioni; William P Cheshire; Thomas Chelimsky; Pietro Cortelli; Christopher H Gibbons; David S Goldstein; Roger Hainsworth; Max J Hilz; Giris Jacob; Horacio Kaufmann; Jens Jordan; Lewis A Lipsitz; Benjamin D Levine; Phillip A Low; Christopher Mathias; Satish R Raj; David Robertson; Paola Sandroni; Irwin Schatz; Ron Schondorff; Julian M Stewart; J Gert van Dijk
Journal:  Clin Auton Res       Date:  2011-04       Impact factor: 4.435

7.  (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

Authors:  S Orimo; E Ozawa; S Nakade; T Sugimoto; H Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

Review 8.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

Authors:  W R Gibb; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-06       Impact factor: 10.154

9.  Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET.

Authors:  Trine Gjerløff; Tatyana Fedorova; Karoline Knudsen; Ole L Munk; Adjmal Nahimi; Steen Jacobsen; Erik H Danielsen; Astrid J Terkelsen; John Hansen; Nicola Pavese; David J Brooks; Per Borghammer
Journal:  Brain       Date:  2014-12-23       Impact factor: 13.501

Review 10.  Parkinson disease subtypes.

Authors:  Mary Ann Thenganatt; Joseph Jankovic
Journal:  JAMA Neurol       Date:  2014-04       Impact factor: 18.302

View more
  7 in total

1.  Wearable sensor device-based detection of decreased heart rate variability in Parkinson's disease.

Authors:  Masashi Suzuki; Tomohiko Nakamura; Masaaki Hirayama; Masamichi Ueda; Mai Hatanaka; Yumiko Harada; Masahiro Nakatochi; Daisuke Nakatsubo; Satoshi Maesawa; Ryuta Saito; Koichi Fujiwara; Masahisa Katsuno
Journal:  J Neural Transm (Vienna)       Date:  2022-07-14       Impact factor: 3.850

2.  Heart-brain synchronization breakdown in Parkinson's disease.

Authors:  Jesus M Cortes; Inigo Gabilondo; Martin Iniguez; Antonio Jimenez-Marin; Asier Erramuzpe; Marian Acera; Beatriz Tijero; Ane Murueta-Goyena; Rocio Del Pino; Tamara Fernandez; Mar Carmona-Abellan; Alberto Cabrera-Zubizarreta; Juan Carlos Gómez-Esteban
Journal:  NPJ Parkinsons Dis       Date:  2022-05-30

3.  Cardiac and peripheral vasomotor autonomic functions in late-onset transthyretin Val30Met familial amyloid polyneuropathy.

Authors:  Haruki Koike; Tomohiko Nakamura; Atsushi Hashizume; Ryoji Nishi; Shohei Ikeda; Yuichi Kawagashira; Masahiro Iijima; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2017-10-05       Impact factor: 4.849

Review 4.  Parkinson's Disease: From Pathogenesis to Pharmacogenomics.

Authors:  Ramón Cacabelos
Journal:  Int J Mol Sci       Date:  2017-03-04       Impact factor: 5.923

5.  Power spectral analysis of heart rate variability is useful as a screening tool for detecting sympathetic and parasympathetic nervous dysfunctions in Parkinson's disease.

Authors:  Tomo Miyagi; Masanobu Yamazato; Takuto Nakamura; Takashi Tokashiki; Yukihiro Namihira; Kazuhito Kokuba; Satoshi Ishihara; Hirokuni Sakima; Yusuke Ohya
Journal:  BMC Neurol       Date:  2022-09-10       Impact factor: 2.903

6.  Association of decreased variation of coefficient R-R interval with ischemic colitis and small bowel obstruction.

Authors:  Toshio Arai; Hiroki Yamada; Takeya Edagawa; Satoshi Yoshida; Shigetoshi Hikimoto; Hiromichi Sougawa; Kenichiro Nakachi
Journal:  PLoS One       Date:  2020-02-12       Impact factor: 3.240

7.  Parkinson-like early autonomic dysfunction induced by vagal application of DOPAL in rats.

Authors:  Jie Sun; Chao He; Qiu-Xin Yan; Hong-Dan Wang; Ke-Xin Li; Xun Sun; Yan Feng; Rong-Rong Zha; Chang-Peng Cui; Xue Xiong; Shan Gao; Xue Wang; Rui-Xue Yin; Guo-Fen Qiao; Bai-Yan Li
Journal:  CNS Neurosci Ther       Date:  2021-01-21       Impact factor: 5.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.